Head-To-Head Contrast: CASI Pharmaceuticals (NASDAQ:CASI) versus NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Profitability

This table compares NRx Pharmaceuticals and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Analyst Recommendations

This is a summary of current ratings and price targets for NRx Pharmaceuticals and CASI Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2	0	5	0	2.43
CASI Pharmaceuticals	1	0	0	0	1.00

NRx Pharmaceuticals currently has a consensus price target of $34.50, indicating a potential upside of 1,110.53%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Insider & Institutional Ownership

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares NRx Pharmaceuticals and CASI Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23 million	100.33	-$28.62 million	($0.55)	-5.18
CASI Pharmaceuticals	$26.85 million	0.10	-$39.26 million	($3.01)	-0.07

NRx Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NRx Pharmaceuticals has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Summary

NRx Pharmaceuticals beats CASI Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.